Microbleed prevalence and burden in anticoagulant-associated intracerebral bleed

Ann Clin Transl Neurol. 2019 Aug;6(8):1546-1551. doi: 10.1002/acn3.50834. Epub 2019 Jul 10.

Abstract

Prior studies suggest an association between Vitamin K antagonists (VKA) and cerebral microbleeds (CMBs); less is known about nonvitamin K oral anticoagulants (NOACs). In this observational study we describe CMB profiles in a multicenter cohort of 89 anticoagulation-related intracerebral hemorrhage (ICH) patients. CMB prevalence was 51% (52% in VKA-ICH, 48% in NOAC-ICH). NOAC-ICH patients had lower median CMB count [2(IQR:1-3) vs. 7(4-11); P < 0.001]; ≥5 CMBs were less prevalent in NOAC-ICH (4% vs. 31%, P = 0.006). This inverse association between NOAC exposure and high CMB count persisted in multivariable logistic regression models adjusting for potential confounders (OR 0.10, 95%CI: 0.01-0.83; P = 0.034).

Publication types

  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Anticoagulants / therapeutic use*
  • Cerebral Hemorrhage / drug therapy*
  • Cohort Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prevalence
  • Retrospective Studies
  • Stroke
  • Vitamin K / antagonists & inhibitors
  • Vitamin K / therapeutic use*

Substances

  • Anticoagulants
  • Vitamin K